tradingkey.logo
tradingkey.logo
Search

Biohaven Says FDA Extends PDUFA Date Of Biohaven's Troriluzole NDA For Rare Disease Spinocerebellar Ataxia

ReutersMay 14, 2025 10:45 PM

- Biohaven Ltd BHVN.N:

  • FDA EXTENDS PDUFA DATE OF BIOHAVEN'S TRORILUZOLE NDA FOR RARE DISEASE SPINOCEREBELLAR ATAXIA

  • BIOHAVEN LTD - FDA'S DECISION REGARDING NDA IS NOW EXPECTED IN 4Q 2025.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI